Northland initiated coverage of Avita Medical (RCEL) with an Outperform rating and $10 price target With about 5% penetration of a roughly $1.3B total addressable market, differentiated products, and reimbursement stabilization, the firm sees the company “revisiting double-digit revenue growth,” the analyst tells investors. The firm also notes Avita is on track to achieve cash breakeven during FY27.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical initiated with an Outperform at Northland
- Avita Medical Earnings Call Signals Stabilizing Growth
- Reimbursement Clarity and Growing Burn Center Adoption Underpin Bullish Outlook for RECELL’s $1.3B Market Opportunity
- Avita Medical reports Q4 EPS (38c), consensus (55c)
- Avita Medical sees FY26 revenue $80M-$85M, consensus $123.5M